316 related articles for article (PubMed ID: 29846894)
1. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
[TBL] [Abstract][Full Text] [Related]
2. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of NF2 gene deletion in pediatric meningiomas using chromogenic in situ hybridization.
Begnami MD; Rushing EJ; Santi M; Quezado M
Int J Surg Pathol; 2007 Apr; 15(2):110-5. PubMed ID: 17478763
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
[TBL] [Abstract][Full Text] [Related]
7. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
8. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
9. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
10. Systemic and local immunosuppression in patients with high-grade meningiomas.
Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
[TBL] [Abstract][Full Text] [Related]
11. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.
Peyre M; Salaud C; Clermont-Taranchon E; Niwa-Kawakita M; Goutagny S; Mawrin C; Giovannini M; Kalamarides M
Oncotarget; 2015 Oct; 6(32):32713-22. PubMed ID: 26418719
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
13. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and molecular characteristics of pediatric meningiomas.
Battu S; Kumar A; Pathak P; Purkait S; Dhawan L; Sharma MC; Suri A; Singh M; Sarkar C; Suri V
Neuropathology; 2018 Feb; 38(1):22-33. PubMed ID: 28901666
[TBL] [Abstract][Full Text] [Related]
15. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
16. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
17. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Sahm F; Bissel J; Koelsche C; Schweizer L; Capper D; Reuss D; Böhmer K; Lass U; Göck T; Kalis K; Meyer J; Habel A; Brehmer S; Mittelbronn M; Jones DT; Schittenhelm J; Urbschat S; Ketter R; Heim S; Mawrin C; Hainfellner JA; Berghoff AS; Preusser M; Becker A; Herold-Mende C; Unterberg A; Hartmann C; Kickingereder P; Collins VP; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Nov; 126(5):757-62. PubMed ID: 24096618
[TBL] [Abstract][Full Text] [Related]
18. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.
Pepe F; Pisapia P; Del Basso de Caro ML; Conticelli F; Malapelle U; Troncone G; Martinez JC
Histol Histopathol; 2020 Jul; 35(7):741-749. PubMed ID: 31872418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
